Kidney Week

Translational Session

Translating Kidney Research Pathways into Novel Drugs: Lesson Learned as We Usher in the Future

October 25, 2020 | 10:00 AM - 12:00 PM

Location: On-Demand

Session Description

The need for novel drugs that target renal cells is larger than ever, with an increasing number of people developing kidney diseases. The drug regulatory pathway has been modified to facilitate the development of novel agents. The translation of discovered pathways into concepts and ultimately drug development has the potential to affect kidney health in a large number of patients. This session reviews what has been learned from these developments, which are supported by KidneyX, a public-private partnership to spark innovation.

Learning Objective(s)

• Outline the regulatory and drug development pathway for novel drugs
• Identify the different drugs that can affect people with kidney diseases
• Discuss new tools, databases, big data, and initiatives that help spark innovation and develop new agents
• Describe animal and in silico models for kidney disease
• Explain the role of stem cells and organoids in drug discovery and regenerative renal medicine

Learning Pathway(s)

• Glomerular Diseases
• Chronic Kidney Disease

Moderators

• Jenny C. Nystrom, PhD
• Martin R. Pollak, MD

Presentations

• Regulatory Pathways and Drug Development Milestones: Lessons Learned
  10:00 AM - 10:30 AM
  Aliza M. Thompson, MD, MS
  

  Aliza M. Thompson, MD, MS

Regulatory Pathways and Drug Development Milestones: Lessons Learned

October 25, 2020 | 10:00 AM - 10:30 AM

Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.

• Drug Screens, Assay Systems, and Big Data Integration Aiding Kidney Drug Development
  10:30 AM - 11:00 AM
  Vineet Gupta, PhD
  

  Vineet Gupta, PhD

Drug Screens, Assay Systems, and Big Data Integration Aiding Kidney Drug Development

October 25, 2020 | 10:30 AM - 11:00 AM

Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.

• Which Drug for Which Disease? Small Molecules to Antibodies to Devices
  11:00 AM - 11:30 AM
  Matthew Douglas Breyer, MD, FASN 
  

  Matthew Douglas Breyer, MD, FASN

  Matthew D. Breyer, MD (Distinguished Scientist CVM Janssen): Dr. Breyer received his M.D from Harvard in 1979. Following residency and nephrology training he served as Professor of Medicine in the division of Nephrology at Vanderbilt University Medical School from 1985-2007, where his work focused on causes of diabetic kidney disease and hypertension through the use of transgenic mouse models. Dr. Breyer has received numerous NIH and VA grant awards and from 2001-2006 headed the nephropathy sub-group of the NIH Animal Models of Diabetic Complications Consortium (AMDCC). As a result of his interest in developing treatments for diabetic nephropathy he moved to Eli Lilly in 2007 to oversee a program to develop bio-therapeutics for diabetic kidney disease. In 2009 he was appointed to the position of Chief Scientific Officer Lead Generation Biotechnology Discovery Research at Eli Lilly where he oversaw preclinical target identification and validation of biologics for chronic kidney, metabolic, neurologic, and oncologic diseases, where he served until 2018. In April 2018 Dr. Breyer joined a new Janssen Cardiovascular and metabolism group in Boston where he guides discovery and development of new drugs for kidney disease.

Which Drug for Which Disease? Small Molecules to Antibodies to Devices

October 25, 2020 | 11:00 AM - 11:30 AM

Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.

• KidneyX: A New Path for Innovation, Diagnosis, and Treatment of Kidney Diseases
  11:30 AM - 12:00 PM
  John R. Sedor, MD, FASN 
  

  John R. Sedor, MD, FASN

  John Sedor is the Ray W. Gifford, M.D., Endowed Chair in Kidney Research at the Cleveland Clinic and a Professor of Molecular Medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. He is the Chair of the KidneyX Steering Committee.

KidneyX: A New Path for Innovation, Diagnosis, and Treatment of Kidney Diseases

October 25, 2020 | 11:30 AM - 12:00 PM

Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.